表紙
市場調査レポート

医薬品有力企業シリーズ:主要医薬品製造受託機関 (CMO) 上位30社 - 市場・産業・動向・技術・展望 2015-2025年

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOS) - Market, Industry, Trends, Technologies and Prospects 2015-2025

発行 Visiongain Ltd 商品コード 274875
出版日 ページ情報 英文 327 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=135.00円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品有力企業シリーズ:主要医薬品製造受託機関 (CMO) 上位30社 - 市場・産業・動向・技術・展望 2015-2025年 Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOS) - Market, Industry, Trends, Technologies and Prospects 2015-2025
出版日: 2015年09月25日 ページ情報: 英文 327 Pages
概要

当レポートでは、世界の主要な医薬品製造受託機関 (CMO) 30社のプロファイルを提供しており、企業の受託生産サービス・オペレーションの概要、近年の財務実績の分析、発展動向の評価、SWOT分析、および収益予測など、体系的な情報を提供しています。

第1章 調査概要

第2章 イントロダクション:医薬品製造受託市場

  • 製造受託企業が提供するサービスとは?
  • 医薬品製造受託市場
  • 医薬品製造受託市場の展望
  • 医薬品製造受託市場の促進因子・阻害因子
  • 主な製造受託企業

第3章 北米の主な医薬品製造受託機関 (CMO)

  • Catalent Pharma Solutions:世界有数のCMOのひとつ
  • Patheon:CMO上位3社の一角
  • Baxter BioPharma Solutions
  • AbbVie Contract Manufacturing
  • Pfizer CentreSource

第4章 欧州の主な医薬品製造受託機関 (CMO)

  • Lonza
  • Evonik Degussa
  • Royal DSM:世界有数のCMO
  • Boehringer Ingelheim Biopharmaceuticals
  • Fareva
  • Aenova Group
  • Famar
  • Vetter Pharmaceutical
  • Almac Group
  • Delpharm
  • Siegfried
  • Corden Pharmaceutical
  • Recipharm
  • Aesica Pharmaceuticals

第5章 日本の主な医薬品製造受託機関 (CMO)

  • ニプロ:日本有数のCMO
  • ダイト株式会社

第6章 先進市場における主なAPIメーカー

  • Teva API
  • Esteve Quimica
  • Euticals

第7章 中国の主な医薬品製造受託企業

  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals
  • Shandong Xinhua Pharmaceutical

第8章 インドの主な医薬品受託製造企業

  • Aurobindo Pharma
  • Divis Laboratories
  • Dr. Reddy's Laboratories

第9章 調査インタビュー

第10章 結論

  • 近年のCMO市場リーダーにとっての成長促進因子は?
  • 成長戦略:主要CMOの展望
  • 生物医薬品製造サービスの高い需要
  • 新技術への投資
  • APIメーカーの展望

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0067

Contracted drug production - stay ahead now by exploring leading companies' prospects

How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's updated report shows you their prospects to 2025. You discover that outsourcing industry's results, trends, opportunities and potentials, also with predicted revenues and profits.

Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market's potential, benefiting your reputation for commercial insight.

That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.

Forecasts and other data to help you stay ahead, benefiting your influence

In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.

Our study gives you 185 tables, 111 charts and three interviews with companies.

That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025:

  • Active pharmaceutical ingredients (API) production
  • Finished dosage formulations (FDF) manufacturing.

In particular, biologics and biosimilars hold promise. New therapies - including antibody-drug conjugates, high potency APIs and regenerative medicines - increasingly interest CMOs and clients.

Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.

Company profiles - explore commercial activities, results, competition and prospects

Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:

  • Overview of the company's contract manufacturing services and operations
  • Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins
  • Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
  • SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
  • Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.

Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry's participants offer - along with their trends and revenue potentials - helping you stay ahead in knowledge and benefit your authority.

European contract manufacturing organisations

Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:

  • Lonza
  • Evonik Degussa
  • Royal DSM
  • Boehringer Ingelheim
  • Fareva
  • Famar
  • Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?

CMOs based in the US and Japan

Our report also shows you developments and business outlooks for seven other international drug production contractors:

  • Catalent Pharma Solutions
  • Patheon
  • Baxter BioPharma Solutions
  • AbbVie Contract Manufacturing
  • Pfizer CentreSource
  • Daito Pharmaceutical
  • Nipro Corporation.

Our work reveals where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2015. You discover where prospects for sales expansion exist, seeing what is possible for that business and its leading competitors.

Developed-market API specialists

You also discover outlooks for three top producers of active pharmaceutical ingredients:

  • Teva API
  • Esteve Química
  • Euticals.

Our report shows commercial potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.

India and China - analysis of pharma manufacturing service providers

Our work assesses six Indian and Chinese companies. You discover activities and prospects of these firms:

  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Divis Laboratories
  • Shandong Xinhua Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals.

That way you find sales data and underlying trends, exploring what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets

Our report also forecasts revenues to 2025 for the world contract manufacturing industry and its main segments: APIs and FDFs.

That work predicts high sales growth from 2015 to 2025. Revenues can reach $80.5bn in 2019, with further expansion possible. We predict large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding commercial potentials.

You also discover interviews with authorities in these three companies, hearing how firms think and view prospects for outsourced drug production:

  • Corden Pharma
  • Siegfried
  • PREMAS Biotech.

With our study you explore opportunities and sales predictions for outsourced production of medicines. You investigate established and rising companies, finding trends, outlooks and revenue potentials. See what is possible.

Ways Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) - Market, Industry, Trends, Technologies and Prospects 2015-2025 helps your work

In particular, our new investigation benefits your research, planning and decisions through the following analyses:

  • Revenues to 2025 for the world pharma contract manufacturing organisations (CMO) market - discover that industry's prospects overall and by submarket, finding promising segments for investments, developments and revenue growth
  • Profiles of 30 leading companies there - assess services, strategies, sales results and outlooks, gaining revenue forecasts to 2025 for 26 of the firms, also with some profitability predictions
  • Interviews with three companies in the CMO industry - explore strategies, debates and opinions, helping you stay ahead in knowledge
  • Competition and opportunities - see what affects that industry, exploring what shapes its future, esp. prospects for sustaining and developing business
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and succeed.

That report, by visiongain's in-house analysts in the UK, gives analysis with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.

Information there found nowhere else, helping you research, analyse and plan

Our survey gives independent analysis. There you gain competitive intelligence found only in our report, exploring leading CMOs and their potentials.

By choosing our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses and decisions. Also see how you could save time and gain in recognition for technological and commercial insight.

Prospects for pharma manufacturing service providers - try our new analysis now

Our new investigation gives you data, trends and business predictions for outsourced drug and API production. Avoid missing out - instead please get our report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Leading Contract Manufacturing Organisations (CMOs) Overview
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers Information
  • 1.4. Main Questions This Report Answers
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Related Reports
  • 1.9. About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2015

  • 2.1. What Services Do Contract Manufacturers Offer?
    • 2.1.1. Why Do Firms Outsource Manufacturing?
    • 2.1.2. What Is Driving Demand for Contract Manufacturing Services?
  • 2.2. The Pharmaceutical Contract Manufacturing Market, 2014
    • 2.2.1. Where is Supply and Demand Highest for Contract Manufacturing Services?
  • 2.3. Outlook for the Pharmaceutical Contract Manufacturing Market 2015-2025
  • 2.4. Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2015-2025
    • 2.4.1. Pharmaceutical Contract Manufacturing: Market Drivers 2015-2025
    • 2.4.2. Pharmaceutical Contract Manufacturing: Market Restraints 2015-2025
  • 2.5. Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?

3. Leading CMOs in North America

  • 3.1. Catalent Pharma Solutions- One of the World's Leading CMO
    • 3.1.1. Catalent: Manufacturing Services and Capabilities
    • 3.1.2. Divisional Segmentation - Breaking Down Catalent's Service
    • 3.1.3. Catalent Pharma's Revenue Growth, 2010-2014
    • 3.1.4. Sustained Growth in Oral Products: Catalent Pharma's Divisional Performance, 2010-2014
    • 3.1.5. Catalent Is Expanding its Oral Technologies Division
    • 3.1.6. Quadrupling Biopharmaceutical Manufacturing Capacity
    • 3.1.7. Expansion of Packaging Services in Asia-Pacific and Europe: 2015
    • 3.1.8. Adding New Early-Stage Development Services
    • 3.1.9. Expansion in Japan - Growth Prospects for Catalent
    • 3.1.10. New Business Contracts 2014-2015
    • 3.1.11. Catalent New Products Launch
    • 3.1.12. Catalent: Opportunities for Growth 2015-2025
    • 3.1.13. Catalent: Mild Growth in Revenue, 2015-2025
  • 3.2. Patheon - One of The Top 3 CMOs
    • 3.2.1. Patheon - Global leader in Pharmaceutical Development Services
    • 3.2.2. Contract Manufacturing Services at Patheon
    • 3.2.3. Steady Revenue Growth 2010-2014
    • 3.2.4. DPx Holdings: Developments
    • 3.2.5. Adding New Formulations and Formulation Development Services
    • 3.2.6. Reassessing Manufacturing Capacity
    • 3.2.7. Expanding Services Through Acquisition, 2015
    • 3.2.8. Patheon: SWOT Analysis 2015-2025
    • 3.2.9. Patheon: Contract Manufacturing Revenue Forecast 2015-2025
  • 3.3. Baxter BioPharma Solutions
    • 3.3.1. Baxter BioPharma is the Global Leader in Sterile Fill and Finish
    • 3.3.2. Historic Revenue Performance 2010-2014
    • 3.3.3. Baxter BioPharma SWOT Analysis 2015-2025
    • 3.3.4. Baxter BioPharma Revenue Forecast 2015-2025
  • 3.4. AbbVie Contract Manufacturing
    • 3.4.1. AbbVie Offers Full-Service Contract Manufacturing
    • 3.4.2. Expanding and Adding New Services: 2013-2014
    • 3.4.3. AbbVie Contract Manufacturing: Revenue 2011-2014
    • 3.4.4. Biologics and HPAPIs Are an Opportunity for Growth 2015-2025
    • 3.4.5. AbbVie Contract Manufacturing Revenue Forecast 2015-2025
  • 3.5. Pfizer CentreSource
    • 3.5.1. Pfizer CentreSource: Historic Revenue Performance, 2010-2014
    • 3.5.2. Will Pfizer Divest CentreSource?
    • 3.5.3. Outlook for CentreSource: Revenue Forecast 2015-2025

4. Leading European Contract Manufacturing Organisations

  • 4.1. Lonza
    • 4.1.1. Lonza Is a Leader in Biologics Manufacturing
    • 4.1.2. Lonza Contract Manufacturing and Development: 2010-2014
    • 4.1.3. Investing in Advanced Biological Drug Sectors
    • 4.1.4. The Promise of Antibody-Drug Conjugates (ADCs)
    • 4.1.5. The Regenerative Medicine Future in Japan
    • 4.1.6. Lonza: SWOT Analysis 2015-2025
    • 4.1.7. Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2015-2025
  • 4.2. Evonik Degussa
    • 4.2.1. Investing in API and Drug Delivery Services
    • 4.2.2. Moderate Growth in Pharmaceutical Manufacturing Services, 2010-2014
    • 4.2.3. Evonik Is a HPAPI Specialist
    • 4.2.4. Evonik Continues to Grow Across All Segments
    • 4.2.5. How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
    • 4.2.6. Evonik Degussa: Revenue Forecast 2015-2025
  • 4.3. Royal DSM - The World's Leading CMO
    • 4.3.1. Amplified Revenue Growth in Pharma Manufacturing 2010-2014
    • 4.3.2. DSM Pharmaceuticals Products: Manufacturing Services 2010-2014
    • 4.3.3. DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
    • 4.3.4. DPx Holdings: A New Pharma Leader
    • 4.3.5. Investing in Biopharma Manufacturing
    • 4.3.6. Expanding API Manufacturing
    • 4.3.7. Generics and Biologics Are an Opportunity for Growth, 2014-2025
    • 4.3.8. DSM Pharmaceuticals Products: Revenue Forecast 2015-2025
  • 4.4. Boehringer Ingelheim Contract Manufacturing
    • 4.4.1. Expanding Biopharmaceuticals Manufacturing Services in China
    • 4.4.2. Production Through to Fill and Finished Biopharmaceuticals
    • 4.4.3. A Track Record of Production for 29 Biopharma Products
    • 4.4.4. Increasing Revenue from Contract Manufacturing, 2010-2014
    • 4.4.5. Pulling Out of Small Molecule API Manufacturing
    • 4.4.6. Expanding through New Services
    • 4.4.7. Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2015-2025
    • 4.4.8. Boehringer Ingelheim: Revenue Forecast 2015-2025
  • 4.5. Fareva
    • 4.5.1. Fareva Has 35 Years' Manufacturing Experience
    • 4.5.2. Revenue Growth through Acquisitions: 2010-2014
    • 4.5.3. Fareva SWOT Analysis: 2015
    • 4.5.4. Fareva Revenue Forecast: 2015-2025
  • 4.6. Aenova Group
    • 4.6.1. Acquisition of Haupt Creates European CMO Giant
    • 4.6.2. Aenova's Ever Expanding Manufacturing Capacity
    • 4.6.3. Aenova's Revenue 2010-2014: Organic Growth and Acquisitions
    • 4.6.4. Aenova's Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2015
    • 4.6.5. Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2015-2025
  • 4.7. Famar
    • 4.7.1. Famar Is an Expert in Lyophilisation
    • 4.7.2. Sustained Growth in Famar's Revenue: 2010-2014
    • 4.7.3. Expanding European Operations
    • 4.7.4. Further Site Acquisitions Are an Opportunity for Growth 2015-2025
    • 4.7.5. How Will Famar Perform 2015-2025?
  • 4.8. Vetter Pharmaceutical
    • 4.8.1. Vetter is an Injectable Manufacturing Specialist
    • 4.8.2. Rapidly Growing Revenue in the US and Germany: 2010-2014
    • 4.8.3. Services, Collaborations and Differentiating Factors
    • 4.8.4. Expanding Services in US and Asia
    • 4.8.5. Biologics Are an Opportunity for Growth for Vetter 2015-2025
    • 4.8.6. Vetter Outlook: Revenue Forecast 2015-2025
  • 4.9. Almac Group
    • 4.9.1. Almac's Manufacturing Services
    • 4.9.2. Almac Outpaces the Market: 2011-2014
    • 4.9.3. Almac Adding Capacity Globally
    • 4.9.4. New Services Added 2012-2015
    • 4.9.5. Almac Group: Contract Manufacturing Market Outlook 2015-2025
    • 4.9.6. How Will Almac Group Perform 2015-2025?
  • 4.10. Delpharm
    • 4.10.1. Finished Dosage Form Manufacturing for Developed Markets
    • 4.10.2. Delpharm: Rapid Revenue Growth Via Acquisitions, 2010-2014
    • 4.10.3. Delpharm: Outlook and Prospects for Growth 2015-2025
    • 4.10.4. Generics Will Drive Revenue Growth for Delpharm 2015-2025
  • 4.11. Siegfried
    • 4.11.1. Siegfried's Acquisitions, 2010-2014
    • 4.11.2. Expanding Siegfried's Manufacturing Footprint Globally
    • 4.11.3. Expanding High Potency API Capabilities
    • 4.11.4. Siegfried: Financial Performance 2010-2014
    • 4.11.5. Siegfried's Characteristics within the Contract Manufacturing Market: SWOT Analysis 2015
    • 4.11.6. Continued Revenue Growth for Siegfried 2015-2025
  • 4.12. Corden Pharmaceutical
    • 4.12.1. CordenPharma Service Division
    • 4.12.2. CordenPharma Emerging in the API Market
    • 4.12.3. Investments in Highly Potent Capabilities
    • 4.12.4. CordenPharma: SWOT Analysis 2015-2025
  • 4.13. Recipharm
    • 4.13.1. Contract Development and Manufacturing Services
    • 4.13.2. Recipharm: Financial Performance 2010-2014
    • 4.13.3. Recipharm Invests in Facility Expansion
    • 4.13.4. Recipharm Growing in Development & Technology Market through Acquisitions
    • 4.13.5. Recipharm: Opportunities for Growth 2015-2025
    • 4.13.6. Outlook for Recipharm: Revenue Forecast 2015-2025
  • 4.14. Aesica Pharmaceuticals
    • 4.14.1. Aesica Manufactures APIs and Finished Dosage Forms
    • 4.14.2. Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2010-2014
    • 4.14.3. Partnering with Academia for Innovative Solutions
    • 4.14.4. Growth through Acquisitions and Internal Expansion
    • 4.14.5. Aesica: Opportunities for Expansion 2015-2025
    • 4.14.6. Forecast Aesica Financial Performance, 2015-2025

5. Leading Japanese Pharma Contract Manufacturing Organisations

  • 5.1. Nipro Corporation: Japan's Leading CMO
    • 5.1.1. Nipro Pharmaceutical Contract Manufacturing Capabilities
    • 5.1.2. Nipro: Decline in Revenue But Increasing Operating Profits 2010-2014
    • 5.1.3. Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2015
    • 5.1.4. Nipro Revenue and Profitability Forecast 2015-2025
  • 5.2. Daito Pharmaceutical
    • 5.2.1. Daito Has a Portfolio of More than 30 APIs
    • 5.2.2. Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2010-2014
    • 5.2.3. Daito Is Well-Placed for Asian Market Growth - SWOT Analysis 2015-2025
    • 5.2.4. Sustained Growth in Revenue and Operating Profit for Daito, 2015-2025

6. Leading Developed-Market API Specialists

  • 6.1. Teva API
    • 6.1.1. API Manufacturing Services
    • 6.1.2. Teva API: Financial Performance 2010-2014
    • 6.1.3. Building a Footprint in Mexico, India and China
    • 6.1.4. Teva API: SWOT Analysis 2015
    • 6.1.5. Outlook for Teva API: Revenue Forecast 2015-2025
  • 6.2. Esteve Química
    • 6.2.1. Esteve Química Manufactures APIs for Developed and Emerging Markets
    • 6.2.2. Expanding in The US, 2015
    • 6.2.3. Esteve Química: SWOT Analysis 2015-2025
  • 6.3. Euticals
    • 6.3.1. Euticals Manufactures More than 200 APIs
    • 6.3.2. Acquisitions Drive Growth 2010-2014
    • 6.3.3. Adding Capacity for Finished Dosage Forms
    • 6.3.4. Asian Expansion Is an Opportunity for Growth 2015-2025
    • 6.3.5. Euticals: Revenue Forecast 2015-2025

7. Leading Chinese Pharmaceutical Contract Manufacturers

  • 7.1. Zhejiang Hisun Pharmaceutical
    • 7.1.1. API Manufacturing for Markets Worldwide
    • 7.1.2. Zhejiang Hisun's Rapid Growth in API Revenue Grows, 2010-2014
    • 7.1.3. Moving Into International Drug Marketing
    • 7.1.4. Zhejiang Hisun: Opportunities for Growth 2015-2025
    • 7.1.5. Zhejiang Hisun: Strong API Revenue Growth 2015-2025
  • 7.2. Zhejiang Huahai Pharmaceuticals
    • 7.2.1. Zhejiang Huahai Is a Market Leader Within The Antihypertensive API Market
    • 7.2.2. Zhejiang Huahai: Contract Manufacturing Performance 2010-2014
    • 7.2.3. Expanding in the US Generic Drugs Market
    • 7.2.4. Zhejiang Huahai: SWOT Analysis, 2015
    • 7.2.5. Zhejiang Huahai: Revenue Forecast, 2015-2025
  • 7.3. Shandong Xinhua Pharmaceutical
    • 7.3.1. Experience in APIs and Finished Dosage Forms
    • 7.3.2. Shandong Xinhua: Strong Revenue Growth 2010-2014
    • 7.3.3. Growing through Joint Ventures
    • 7.3.4. Looking to Expand in the US and EU 2015-2025
    • 7.3.5. Shandong Xinhua Pharmaceutical: Revenue Forecast 2015-2025

8. Leading Indian Pharmaceutical Contract Manufacturers

  • 8.1. Aurobindo Pharma
    • 8.1.1. API Manufacturing Services
    • 8.1.2. Aurobindo Pharma: Steady Revenue Growth 2010-2014
    • 8.1.3. Aurobindo Expanding Outside of Antibacterials
    • 8.1.4. Aurobindo: Opportunities for Expansion 2015-2025
    • 8.1.5. How Will Aurobindo's Contract Manufacturing Division Perform 2015-2025?
  • 8.2. Divis Laboratories
    • 8.2.1. Divis Laboratories and the Contract Manufacturing Industry
    • 8.2.2. Divis Laboratories: A Rapidly Growing CMO, 2010-2014
    • 8.2.3. Divis Laboratories: API Manufacturing Outlook 2015-2025
    • 8.2.4. Divis Laboratories: API Manufacturing Revenue Forecast, 2015-2025
  • 8.3. Dr. Reddy's Laboratories
    • 8.3.1. API and FDF Manufacturing Services
    • 8.3.2. Dr. Reddy's PSAI: Strong Revenue Growth 2010-2014
    • 8.3.3. Advancing in Complex Drug Manufacturing
    • 8.3.4. Expanding in the European Manufacturing Market
    • 8.3.5. Dr. Reddy's PSAI Division: Revenue Forecast 2015-2025

9. Research Interviews from Our Industry Survey

  • 9.1. Dr Michael Quirmbach, Vice President, Global Sales & Marketing, CPI, Corden Pharma
  • 9.2. Mrs Marianne Spaene, Executive Vice President, Global Head Business Development, Sales and Marketing, Siegfried
  • 9.3. Dr Prabuddha Kundu, Cofounder & Executive Director, PREMAS Biotech

10. Conclusions of the Study

  • 10.1. What Has Driven Growth for CMO Market Leaders in Recent Years?
  • 10.2. Strategies for Growth: Prospects For Leading CMOs, 2015-2025
  • 10.3. High Demand for Biopharmaceutical Manufacturing Services
  • 10.4. Investing in Novel Technologies
  • 10.5. Outlook for API Manufacturers

List of Tables

  • Table 1.1: Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
  • Table 1.2: Foreign Currency Exchange Rates Used: 2014 Average Exchange Rate to $US
  • Table 2.1: Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2015
  • Table 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2012-2014
  • Table 2.3: Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2013
  • Table 2.4: Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2013
  • Table 2.5: Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019 and 2025
  • Table 2.6: Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
  • Table 3.1: Catalent Details, 2015
  • Table 3.2: Catalent Facility Details, 2015
  • Table 3.3: Catalent Financial Performance: Revenue ($m), 2010-2014
  • Table 3.4: Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2014
  • Table 3.5: Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2010-2014
  • Table 3.6: Catalent New Products Launch: New Products, Annual Growth (%), CAGR (%), 2012-2014
  • Table 3.7: Catalent Pharma SWOT Analysis, 2015
  • Table 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
  • Table 3.9: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 3.10: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
  • Table 3.11: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 3.12: Patheon Details, 2015
  • Table 3.13: Patheon Manufacturing Facilities, 2014
  • Table 3.14: Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
  • Table 3.15: Patheon: SWOT Analysis, 2015
  • Table 3.16: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 3.17: Baxter BioPharma Solutions Details, 2015
  • Table 3.18: Baxter BioPharma Solutions: Facilities and Services Offered, 2014
  • Table 3.19: Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 3.20: Baxter BioPharma Solutions SWOT Analysis, 2015
  • Table 3.21: Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 3.22: AbbVie Contract Manufacturing: Details, 2015
  • Table 3.23: AbbVie Contract Manufacturing Facility Capabilities, 2014
  • Table 3.24: AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), CAGR (%), 2011-2014
  • Table 3.25: AbbVie Contract Manufacturing SWOT Analysis, 2015
  • Table 3.26: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 3.27: Pfizer CentreSource Details, 2015
  • Table 3.28: Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 3.29: Pfizer CentreSource SWOT Analysis, 2015
  • Table 3.30: Forecast Pfizer CentreSource Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 4.1: Lonza Details, 2015
  • Table 4.2: Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
  • Table 4.3: Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2010-2014
  • Table 4.4: ADCs Approved and in Late Stage Clinical Development, 2014
  • Table 4.5: Lonza SWOT Analysis, 2015
  • Table 4.6: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2014-2019
  • Table 4.7: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2019-2025
  • Table 4.8: Evonik Degussa Details, 2015
  • Table 4.9: Evonik Health and Nutrition: R&D and Production Sites by Region, 2014
  • Table 4.10: Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 4.11: Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2015
  • Table 4.12: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.13: Royal DSM Details, 2015
  • Table 4.14: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 4.15: DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 4.16: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 4.17: DSM Pharmaceutical Manufacturing: SWOT Analysis, 2015
  • Table 4.18: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
  • Table 4.19: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2019-2025
  • Table 4.20: Boehringer Ingelheim Biopharmaceuticals Details, 2015
  • Table 4.21: Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
  • Table 4.22: Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
  • Table 4.23: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
  • Table 4.24: Boehringer Ingelheim: SWOT Analysis, 2015
  • Table 4.25: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.26: Fareva Details, 2015
  • Table 4.27: Fareva Manufacturing Facilities, 2014
  • Table 4.28: Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 4.29: Fareva: SWOT Analysis, 2015
  • Table 4.30: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.31: Aenova Group Details, 2015
  • Table 4.32: Aenova Group Manufacturing Capacity by Dosage Form, 2015
  • Table 4.33: Aenova Group Manufacturing Facility Details, 2015
  • Table 4.34: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
  • Table 4.35: Aenova Group SWOT Analysis, 2015
  • Table 4.36: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2014-2019
  • Table 4.37: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2019-2025
  • Table 4.38: Famar Details, 2015
  • Table 4.39: Famar Pharmaceutical Manufacturing Facilities, 2014
  • Table 4.40: Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 4.41: Famar: SWOT Analysis, 2015
  • Table 4.42: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.43: Vetter Details, 2015
  • Table 4.44: Vetter Pharmaceutical Manufacturing Facilities, 2014
  • Table 4.45: Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 4.46: Vetter: SWOT Analysis, 2015
  • Table 4.47: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.48: Almac Details, 2015
  • Table 4.49: Almac Pharmaceutical Manufacturing Facilities Details, 2014
  • Table 4.50: Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
  • Table 4.51: Almac: SWOT Analysis, 2015
  • Table 4.52: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2014-2019
  • Table 4.53: Forecast Almac Pharmaceuticals: Revenue ($m), 2019-2025
  • Table 4.54: Delpharm Details, 2015
  • Table 4.55: Delpharm: Facilities and Services, 2014
  • Table 4.56: Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 4.57: Delpharm: SWOT Analysis, 2015
  • Table 4.58: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.59: Siegfried Details, 2015
  • Table 4.60: Siegfried Pharmaceutical Manufacturing Facilities Details, 2015
  • Table 4.61: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
  • Table 4.62: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
  • Table 4.63: Siegfried: SWOT Analysis, 2015
  • Table 4.64: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2014-2019
  • Table 4.65: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2019-2025
  • Table 4.66: CordenPharma Details, 2015
  • Table 4.67: CordenPharma Facilities and Service Details, 2014
  • Table 4.68: Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2014
  • Table 4.69: Corden Pharmaceuticals SWOT Analysis, 2015
  • Table 4.70: Recipharm Details, 2015
  • Table 4.71: Recipharm: Facility Details and Services, 2014
  • Table 4.72: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
  • Table 4.73: Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2014
  • Table 4.74: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2014
  • Table 4.75: Recipharm: SWOT Analysis, 2015
  • Table 4.76: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
  • Table 4.77: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
  • Table 4.78: Aesica Details, 2015
  • Table 4.79: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
  • Table 4.80: Aesica SWOT Analysis, 2015
  • Table 4.81: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
  • Table 4.82: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
  • Table 5.1: Nipro Pharma Details, 2015
  • Table 5.2: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2009-2014
  • Table 5.3: Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2014
  • Table 5.4: Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
  • Table 5.5: Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2015
  • Table 5.6: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
  • Table 5.7: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 5.8: Daito Pharmaceuticals: Details, 2015
  • Table 5.9: Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
  • Table 5.10: Daito Pharmaceuticals SWOT Analysis, 2015
  • Table 5.11: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
  • Table 5.12: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 6.1: Teva API Details, 2015
  • Table 6.2: Teva API: Site Acquisitions, 1980- 2011
  • Table 6.3: Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 6.4: Teva API SWOT Analysis, 2015
  • Table 6.5: Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 6.6: Esteve Química Details, 2015
  • Table 6.7: Esteve Química SWOT Analysis, 2015
  • Table 6.8: Euticals Details, 2015
  • Table 6.9: Euticals Facility Details: Production Capacity (m3) and Key Products, 2015
  • Table 6.10: Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2014
  • Table 6.11: Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 6.12: Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2014
  • Table 6.13: Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2014
  • Table 6.14: Euticals SWOT Analysis, 2015
  • Table 6.15: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 7.1: Zhejiang Hisun Pharmaceuticals Details, 2015
  • Table 7.2: Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 7.3: Zhejiang Hisun Manufacturing: SWOT Analysis, 2015
  • Table 7.4: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 7.5: Zhejiang Huahai Pharmaceuticals Details, 2015
  • Table 7.6: Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 7.7: Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2015
  • Table 7.8: Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 7.9: Shandong Xinhua Pharmaceuticals Details, 2015
  • Table 7.10: Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2015
  • Table 7.11: Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 7.12: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2014
  • Table 7.13: Shandong Xinhua Manufacturing: SWOT Analysis, 2015
  • Table 7.14: Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 8.1: Aurobindo Pharma Details, 2015
  • Table 8.2: Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 8.3: Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
  • Table 8.4: Aurobindo Contract Manufacturing: SWOT Analysis, 2015
  • Table 8.5: Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 8.6: Divis Laboratories Details, 2015
  • Table 8.7: Divis Laboratories: Facility Details, Production Capacity and Services, 2015
  • Table 8.8: Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 8.9: Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2014
  • Table 8.10: Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2014
  • Table 8.11: Divis Laboratories Contract Manufacturing: SWOT Analysis, 2015
  • Table 8.12: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m),EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
  • Table 8.13: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
  • Table 8.14: Dr. Reddy's Laboratories Details, 2015
  • Table 8.15: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
  • Table 8.16: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 8.17: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2014
  • Table 8.18: Dr. Reddy's Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2014
  • Table 8.19: Dr. Reddy's Laboratories: SWOT Analysis, 2015
  • Table 8.20: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 10.1: Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2010-2014
  • Table 10.2: CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2010-2014
  • Table 10.3: Leading CMOs: Combined Annual Revenue ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2025
  • Table 10.4: Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 10.5: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2014-2019
  • Table 10.6: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2019-2025

List of Figures

  • Figure 1.1: Segmentation of Contract Manufacturing Organisations, 2015
  • Figure 2.1: Selected Services Contracted to CMOs by Developmental Stage, 2015
  • Figure 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2012-2014
  • Figure 2.3: Contract Manufacturing Market by Service: Market Share (%), 2013
  • Figure 2.4: Contract Manufacturing Market by Leading Country: Market Share (%), 2013
  • Figure 2.5: Contract Manufacturing Market by Service: Market Size ($bn), 2014, 2019 and 2025
  • Figure 2.6: Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2015-2025
  • Figure 3.1: Catalent Facilities by Region, 2014
  • Figure 3.2: Catalent Facilities by Service Offered, 2014
  • Figure 3.3: Catalent Financial Performance: Revenue ($m), 2010-2014
  • Figure 3.4: Catalent Financial Performance by Product Type: Revenue Share (%), 2014
  • Figure 3.5: Catalent Financial Performance by Division: Revenue ($m), 2010-2014
  • Figure 3.6: Catalent New Products Launch: New products, 2012-2014
  • Figure 3.7: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
  • Figure 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2019-2025
  • Figure 3.9: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2014-2025
  • Figure 3.10: Patheon Pharmaceutical Development Projects (%) by Phase, 2014
  • Figure 3.11: Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2014
  • Figure 3.12: Patheon Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 3.13: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 3.14: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2014-2025
  • Figure 3.15: Baxter BioPharma Manufacturing: Revenue ($m), 2010-2014
  • Figure 3.16: Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2014-2025
  • Figure 3.17: AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2014
  • Figure 3.18: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 3.19: Pfizer CentreSource: Revenue ($m), 2010-2014
  • Figure 3.20: Forecast Pfizer CentreSource Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.1: Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
  • Figure 4.2: Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2014
  • Figure 4.3: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 4.4: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 4.5: Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2014
  • Figure 4.6: Evonik Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.7: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.8: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.9: Royal DSM Pharmaceutical Manufacturing by Division: Revenue ($m), 2010-2014
  • Figure 4.10: DSM Pharmaceutical Products (DPP) Division: Revenue ($m), 2010-2014
  • Figure 4.11: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2010-2014
  • Figure 4.12: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2014-2025
  • Figure 4.13: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.14: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.15: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.16: Fareva Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.17: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.18: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
  • Figure 4.19: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
  • Figure 4.20: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2019-2025
  • Figure 4.21: Famar Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.22: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.23: Vetter Pharmaceutical Manufacturing: Revenue ($m), 2010-2014
  • Figure 4.24: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.25: Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
  • Figure 4.26: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2014-2019
  • Figure 4.27: Forecast Almac Pharmaceuticals: Revenue ($m), 2019-2025
  • Figure 4.28: Delpharm: Revenue ($m), 2010-2014
  • Figure 4.29: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 4.30: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
  • Figure 4.31: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2010-2014
  • Figure 4.32: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2013
  • Figure 4.33: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2014
  • Figure 4.34: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 4.35: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 4.36: Corden Pharmaceuticals: Revenue ($m), 2012-2014
  • Figure 4.37: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
  • Figure 4.38: Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2014
  • Figure 4.39: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2014
  • Figure 4.40: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 4.41: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 4.42: Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2010-2014
  • Figure 4.43: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 4.44: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 5.1: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2009-2014
  • Figure 5.2: Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2014
  • Figure 5.3: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 5.4: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 5.5: Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2010-2014
  • Figure 5.6: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2014-2019
  • Figure 5.7: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2019-2025
  • Figure 6.1: Teva API: Revenue ($m), 2010-2014
  • Figure 6.2: Forecast Teva API Manufacturing: Revenue ($m), 2014-2025
  • Figure 6.3: Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2014
  • Figure 6.4: Euticals: Revenue ($m), 2010-2014
  • Figure 6.5: Euticals Revenue by Product Class: Share of Total Revenues (%), 2014
  • Figure 6.6: Euticals Revenue by Region: Share of Total Revenues (%), 2014
  • Figure 6.7: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2014-2025
  • Figure 7.1: Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2010-2014
  • Figure 7.2: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2014-2025
  • Figure 7.3: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2010-2014
  • Figure 7.4: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2014-2025
  • Figure 7.5: Shandong Xinhua: Revenue ($m), 2010-2014
  • Figure 7.6: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2014
  • Figure 7.7: Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2014-2025
  • Figure 8.1: Aurobindo Contract Manufacturing: Revenue ($m), 2010-2014
  • Figure 8.2: Aurobindo Contract Manufacturing: Revenue Share (%), 2014
  • Figure 8.3: Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2014-2025
  • Figure 8.4: Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2010-2014
  • Figure 8.5: Divis Laboratories Revenue Distribution: Revenue ($m), 2014
  • Figure 8.6: Divis Laboratories Revenue by Region: Share of Total (%), 2014
  • Figure 8.7: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2014-2019
  • Figure 8.8: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2019-2025
  • Figure 8.9: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2014
  • Figure 8.10: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2010-2014
  • Figure 8.11: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2014
  • Figure 8.12: Dr. Reddy's Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2014
  • Figure 8.13: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2014-2025
  • Figure 10.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($bn), 2010-2014
  • Figure 10.2: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2010-2014
  • Figure 10.3: Leading CMOs: Combined Annual Revenue ($bn), 2014-2025
  • Figure 10.4: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($bn), 2014-2025
  • Figure 10.5: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2014-2019
  • Figure 10.6: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2019-2025

Companies Listed

  • Abbott Laboratories
  • Abic
  • AbbVie
  • Actavis
  • Adamas Pharmaceuticals
  • Aegerion
  • Aenova Group
  • Aesica Pharmaceuticals
  • Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agennix
  • Aguettant
  • AlgoNomics
  • Alliance Medical Products
  • Almac Group
  • Alpharma
  • Amgen
  • AMYRA Biotech
  • Andeno
  • Apexigen
  • Aptuit
  • Archimica
  • Arecor
  • ArGEN-X
  • Astellas
  • AstraZeneca
  • Athera Biotechnologies
  • Aurobindo Pharma
  • Avalanche Biotechnologies
  • Banner Life Sciences
  • BaroFold
  • Barr-Pliva
  • BASF
  • Baxter BioPharma Solutions
  • Bayer
  • BC Partners
  • Becton and Dickinson (BD)
  • Beijing Double-Crane Pharmaceutical
  • Bentley
  • Biocraft
  • Biogal
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Bionomics
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bridgepoint Capital
  • Bristol-Myers Squibb
  • Britest
  • Canyon
  • Carbogen Amcis
  • Cardinal Health
  • Catalent
  • Celladon
  • Celldex Therapeutics
  • Celsion
  • CEVEC Pharmaceuticals
  • Chemtrix BV
  • China National Pharmaceutical Group (SInopharm)
  • Chirotech
  • Circadian Technologies
  • Cleveland BioLabs
  • Cobra Biomanufacturing
  • Companies House
  • CordenPharma
  • Corvette Pharmaceutical Services
  • Daiichi Sankyo
  • Daito
  • DecImmune Therapeutics
  • Delmas Perfusion
  • Delpharm
  • Divis Laboratories
  • DPx Holdings
  • Dr. Reddy's Laboratories
  • Dragenopharm Apotheker Püschl and Swiss Caps
  • Eclipse Therapeutics
  • Eindhoven University of Technology
  • Eisai
  • Eli Lilly
  • EmulTech
  • Esteve Química
  • Euro Vital Pharma
  • European Medicines Agency (EMA)
  • Euticals
  • Evonik Degussa
  • Excella
  • Exelixis
  • Famar
  • Fareva
  • Farmaprojects
  • Frazier Healthcare
  • Fuyang Xinghai Investment
  • Genentech
  • Générique Même Médicament (GEMME)
  • Genzyme
  • GSK
  • Corixa
  • Haupt Pharma
  • Health Canada
  • Hejiang Jiang Yuan Tang Biotechnology
  • Human Genome Sciences
  • ICI
  • Immune Pharmaceuticals
  • Immunomedics
  • Index Ventures
  • Indoco Remedies
  • Intellect Neurosciences
  • International Chemical Investors Group
  • Ivax API
  • Japanese Ministry of Health Labor and Welfare (MHWL)
  • Japanese Pharmaceutical and Medical Devices Agency (PMDA)
  • JK Pharmaceutical
  • JLL Partners
  • Johnson & Johnson (J&J)
  • Kadmon
  • Laboratoires Besins
  • Lanxess Corporation
  • LBO Italia Investimenti s.r.l
  • Lonza
  • Marinopoulos Group.
  • MedImmune
  • Merck KGaA
  • Merck Serono
  • Mesoblast
  • Molecular Partners
  • Moody's Corporation
  • Mylan
  • NIH CRM
  • Nipro Corporation
  • Novartis
  • Novasep
  • Novozymes
  • NPS
  • OctoPlus
  • OncoMed Pharmaceuticals
  • Opthea
  • Osiris Therapeutics
  • Otsuka Pharmaceutical
  • Pantec
  • Patheon
  • Perrigo
  • PFC
  • Pfizer
  • Pharmacia
  • Pharmacyclis
  • Pharmintraco
  • Piramal
  • Plantex
  • Poli Industria Chimica
  • Progenics Pharmaceuticals
  • Prosintex
  • R5 Pharmaceuticals
  • RAG AG
  • Ranbaxy Labs
  • Recipharm
  • Regeneus
  • Relthy Laboratórios
  • Relypsa
  • Respirics
  • Rexim
  • Roche
  • Royal DSM
  • Sandoz
  • Sanofi
  • Sanquin Blood Supply foundation
  • Sanwa Kagaku Kenkyusho
  • Schering
  • ScinoPharm
  • Seattle Genetics
  • Sentry BioPharma Services
  • Servier
  • Shandong Tianda Biological Pharmaceutica
  • Shandong Xinhua Pharmaceutical
  • Shanghai Pharmaceutical
  • ShangPharma
  • Shire
  • Sicor
  • Siegfried
  • Sigmar Italia
  • Silverfleet Capital
  • Sinochem
  • SkyePharma
  • Solvay
  • Sun Pharma
  • Supernus Pharmaceuticals
  • SurModics
  • Swedbank
  • Swedish Orphan Biovitrium AB (Sobi)
  • Synkem
  • Syntex
  • Synthon
  • Takeda
  • Temmler Group
  • Tessenderlo Group
  • Teva Pharmaceutical Industries
  • Theramax
  • Tianjin Tianyo Pharmaceuticals
  • Tianma Tianji
  • Tunitas Therapeutics
  • UCB
  • UK Health and Safety Executive
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • UMN Pharma
  • UniQure
  • University College London (UCL)
  • University of Bradford
  • University of Durham
  • University of Leeds
  • US Food and Drug Administration (FDA)
  • Vetter Pharma
  • Vidara
  • ViroPharma
  • Vivante GMP Solutions
  • VTU Technology
  • West Pharma
  • Wockhardt
  • XOMA
  • Yiwu Huayi Investment
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals
Back to Top